Last year, Emergent BioSolutions Inc generated 223.30M USD for its biggest-performing segment, Commercial Product sales. The Non-U.S Government made the largest contribution, accounting for 403.20M USD last year. For the latest quarter, Emergent BioSolutions Inc reported the revenue of 168.00M USD for the period ending 2026-06-30, which came from the top-performing segment, MCM Product sales. U.S.Government contributed the highest revenue, at 157.10M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Commercial Product sales

MCM Product sales

Contracts and grants

Bioservices

Product sales, net

Contract development and manufacturing services

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

Commercial Product sales

223.30M(50.76%)

398.90M(38.22%)

497.30M(47.39%)

386.60M(34.60%)

438.00M(24.70%)

--(--)

MCM Product sales

156.50M(35.58%)

509.80M(48.85%)

447.20M(42.62%)

579.60M(51.87%)

585.90M(33.03%)

--(--)

Contracts and grants

36.70M(8.34%)

30.00M(2.87%)

26.30M(2.51%)

41.40M(3.70%)

134.20M(7.57%)

115.10M(7.40%)

Bioservices

23.40M(5.32%)

104.90M(10.05%)

78.50M(7.48%)

109.90M(9.83%)

615.50M(34.70%)

--(--)

Product sales, net

--(--)

989.80M(63.64%)

Contract development and manufacturing services

--(--)

450.50M(28.96%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

Non-U.S Government

U.S.Government

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

Non-U.S Government

403.20M(91.66%)

633.10M(60.67%)

654.60M(62.38%)

634.90M(56.81%)

870.30M(49.07%)

566.90M(36.45%)

431.30M(39.00%)

U.S.Government

36.70M(8.34%)

410.50M(39.33%)

394.70M(37.62%)

482.60M(43.19%)

903.30M(50.93%)

988.50M(63.55%)

674.70M(61.00%)